Elizabeth A. Guancial, MD

Accumulating evidence suggests that androgen deprivation therapy for prostate cancer increases the risk of cardiovascular morbidity and mortality, though not all studies demonstrate an association

Imagine navigating through a crowd of 25,000 oncology professionals in the largest conference center in the United States. In this environment, it is easy for even the most seasoned oncologist to feel overwhelmed.